Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma

BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive primary liver cancer, with increasing incidence worldwide. Effective first-line treatments for advanced ICC patients are currently limited. Therefore, our study aimed to assess the efficacy and safety of programmed death-1 (PD-...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jia-Xin, Liu, Bo, Li, Yu, Li, Xi, Ding, Li-Juan, Wang, Nan-Ya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471988/
https://www.ncbi.nlm.nih.gov/pubmed/37664019
http://dx.doi.org/10.3389/fonc.2023.1204486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471988/
https://www.ncbi.nlm.nih.gov/pubmed/37664019
http://dx.doi.org/10.3389/fonc.2023.1204486

Ejemplares similares